Inovio Pharmaceuticals Investors Face Deadline in Securities Class Action
Investors who purchased Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, may be eligible to participate in a securities class action lawsuit. A lead plaintiff deadline of April 7, 2026, has been set for those wishing to direct the litigation.
What’s at Stake? Allegations of Misleading Statements
The lawsuit alleges that Inovio Pharmaceuticals made false and/or misleading statements regarding its business operations. Specifically, the claims center around issues with the manufacturing of the CELLECTRA device, delays in submitting the INO-3107 Biologics License Application (BLA) to the FDA, and overstated regulatory and commercial prospects for INO-3107. Investors reportedly suffered damages when these details came to light.
Key Allegations Detailed
- Manufacturing Deficiencies: Concerns about the quality and reliability of the CELLECTRA device manufacturing process.
- Delayed BLA Submission: Inovio was allegedly unlikely to submit its BLA for INO-3107 by the projected timeframe of the second half of 2024.
- Questionable FDA Approval Path: Insufficient data to support accelerated or priority review by the FDA.
- Overstated Prospects: An overly optimistic portrayal of the drug’s potential for regulatory success and market performance.
Rosen Law Firm Takes the Lead
Rosen Law Firm, a global investor rights law firm, is spearheading the class action. The firm encourages investors to select qualified counsel with a proven track record in securities litigation. They caution against firms that act merely as “middlemen,” referring cases to other firms without possessing the necessary expertise. Rosen Law Firm highlights its own success, including achieving the largest ever securities class action settlement against a Chinese Company and consistently ranking among the top firms in securities class action settlements.
The firm emphasizes its experience representing investors globally and its focus on securities class actions and shareholder derivative litigation. They have recovered hundreds of millions of dollars for investors, including over $438 million in 2019.
How to Participate and Important Considerations
If you purchased Inovio securities during the Class Period, you may be entitled to compensation without out-of-pocket fees through a contingency fee arrangement. To join the class action, you can:
- Visit: https://rosenlegal.com/submit-form/?case_id=52847
- Call: 866-767-3653
- Email: [email protected]
If you wish to serve as lead plaintiff, you must file a motion with the Court by April 7, 2026. It’s important to note that a class has not yet been certified, and you are not automatically represented by counsel unless you retain one. You have the right to choose your own counsel or remain an absent class member.
The Rise of Securities Class Action Lawsuits
Securities class action lawsuits have become increasingly common in recent years, reflecting a growing awareness of investor rights and a more active legal landscape. These lawsuits often arise from allegations of corporate misconduct, such as misleading financial statements or inaccurate disclosures about product development. The potential for significant financial recovery makes these cases attractive to investors who believe they have been harmed by fraudulent or negligent behavior.
Did you know? The number of securities class action filings can fluctuate based on market conditions and regulatory enforcement activity. Periods of market volatility often see an increase in litigation.
FAQ
Q: What is a lead plaintiff?
A: A lead plaintiff is a representative party who directs the litigation on behalf of other class members.
Q: What is a contingency fee arrangement?
A: You only pay legal fees if the case is successful, and the fees are a percentage of the recovery.
Q: Do I have to be the lead plaintiff to receive compensation?
A: No, your ability to share in any potential recovery is not dependent on serving as lead plaintiff.
Q: What if I don’t want to participate?
A: You can remain an absent class member and do nothing at this time.
Pro Tip: Document all your Inovio Pharmaceuticals stock transactions during the Class Period. This information will be crucial if you decide to participate in the lawsuit.
Follow Rosen Law Firm for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
